Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: Pharmacodynamic implications

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 3, 2006, Pages 874-879

  Zhou, Xiao Jian ^a   Lim, Seng Gee ^b   Lloyd, Deborah M ^a   Chao, George C ^a   Brown, Nathaniel A ^a   Lai, Ching Lung ^c  

^a Idenix Pharmaceuticals Inc   (United States)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOMODULATING AGENT; PLACEBO; TELBIVUDINE; VIRUS DNA;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEPATITIS B; HUMAN; MALE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE; VIRUS LOAD;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; COHORT STUDIES; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HALF-LIFE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; NUCLEOSIDES; PYRIMIDINONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33644662858     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.3.874-879.2006     Document Type: Article

References (8)

1. Bridges, E., E. Cretton-Scott, X. J. Zhou, A. Juodawlkis, G. Gosselin, and M. Bryant. 2001. The anti-HBV agent β-L-thymidine (LdT) exhibits no observable effects in chronic developmental toxicity studies, p. 84-85, abstr. 85. Proc., Frontiers in Drug Development for Viral Hepatitis.
2. Bridges, E. G., M. L. Bryant, L. Placidi, A. Faraj, A. G. Loi, C. Pierra, D. Dukhan, G. Gosselin, J. L. Imbach, B. Hernández, A. Juodawlkis, B. Tennant, E. Cretton-Scott, and J. P. Sommadossi. 2001. Toxicological study of the anti-HBV agent β-L-2′-deoxythymidine, p. 263-270. In R. F. Schinazi, J. P. Sommadossi, and C. M. Rice (ed.), Frontiers in viral hepatitis. Elsevier B.V., Amsterdam, The Netherlands.
3. Bryant, M. L., E. G. Bridges, L. Placidi, A. Faraj, A. G. Loi, C. Pierra, D. Dukhan, G. Gosselin, J. L. Imbach, B. Hernández, A. Juodawlkis, B. Tennant, B. Korba, P. Cote, P. Marion, E. Cretton-Scott, R. F. Schinazi, and J. P. Sommadossi. 2001. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother. 45:229-235.
4. Cretton-Scott, E., X. J. Zhou, E. G. Bridges, B. Tennant, A. Juodawlkis, G. Gosselin, J. L. Imbach, C. Pierra, D. Dukhan, R. F. Schinazi, J. P. Sommadossi, and M. Bryant. 1999. Pharmacokinetics of β-L-thymidine and β-L-2′-deoxycytidine in woodchucks and monkeys. Antivir. Ther. 4:A124.
5. Hernandez-Santiago, B., L. Placidi, E. Cretton-Scott, A. Faraj, E. Bridges, M. L. Bryant, J. Rodriguez-Orengo, J. L. Imbach, G. Gosselin, C. Pierra, D. Dukhan, and J. P. Sommadossi. 2001. Pharmacology of β-L-2′-deoxythymidine and β-L-2′-deoxycydine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob. Agents Chemother. 46:1728-1733.
6. Lai, C. L., S. G. Lim, N. A. Brown, X. J. Zhou, D. M. Lloyd, Y. M. Lee, M. F. Yuen, G. C. Chao, and Maureen W. Myers. 2004. A dose-finding study of once-daily oral telbivudine (LdT) in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 40:719-726.
7. Lai, C. L., N. Leung, E. K. Teo, M. Tong, F. Wong, H. W. Hann, S. Han, T. Poynard, M. Myers, G. Chao, D. Lloyd, and N. A. Brown. 2005. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129:528-536.
8. Zhou, X. J., S. G. Lim, C. L. Lai, P. F. Lam, D. M. Pow, N. A. Brown, and M. W. Myers. 2001. Pharmacokinetics of β-L-deoxythymidine (LdT) in healthy subjects and patients with chronic hepatitis B virus infection, p. 92, abstr. 100. Proc., Frontiers in Drug Development for Viral Hepatitis.